Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Medication


Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

January 19th 2021

These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)

Categories: Medication, News
Tags: COVID-19, metformin

Categories: Medication
Tags: COVID-19, metformin

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

January 14th 2021

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: sotagliflozin

Categories: Cardiovascular, Medication
Tags: sotagliflozin

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

January 13th 2021

In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with notable differences in benefits and harms (BMJ)

Categories: Medication
Tags: DPP4i, SGLT2 inhibitors

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

January 11th 2021

In propensity score-matched cohorts, GLP-1 RAs demonstrated significant benefits for both glycemic control and weight management over additional OAD(s) or insulin, respectively, indicating that they may represent the optimal choice at these points in the treatment pathway (BMJ Open, Diabetes Research & Care)

Categories: Medication, News
Tags: GLP1, Type 2 Diabetes

Categories: Medication
Tags: GLP1, Type 2 Diabetes

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:

December 17th 2020

Dapagliflozin reduces the risks of major adverse kidney and cardiovascular events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease (The Lancet)

Categories: Medication, News
Tags: CKD, dapagliflozin

Categories: Medication
Tags: CKD, dapagliflozin

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal disease

December 16th 2020

In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, News
Tags: DPP4, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: DPP4, SGLT2 inhibitors

Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors

December 16th 2020

This analysis indicates unrealized opportunities to reduce mortality in selected veterans with T2D and CAD via increased GLP‐1RA and SGLT2i use (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: GLP1, SGLT2 inhibitors

Categories: Medication
Tags: GLP1, SGLT2 inhibitors

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis

December 13th 2020

For reduction of HbA1c, weight, and SBP in patients uncontrolled on metformin, add-on dual AHAs showed greater improvement compared to single AHAs. These findings can further inform the treatment of T2DM patients uncontrolled on metformin (Diabetes Therapy)

Categories: Medication, News
Tags: Type 2 Diabetes

Categories: Medication
Tags: Type 2 Diabetes

Trends in diabetes medication use in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)

December 7th 2020

Use of combinations of metformin and new drug classes increased in all nations, replacing combinations involving SUs. In 2017 more patients were on DPP4s (between 19.1% and 27.6%) than on SGLT2s (between 10.1% and 15.3%). Conclusions: New drugs are displacing SUs. However, despite evidence of better outcomes, the adoption of SGLT2s lagged behind DPP4s (British Journal of General Practice)

Categories: Medication, News

Categories: Medication

Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study

December 1st 2020

SGLT2 inhibitor administration yielded minimal effects on ARR and did not increase false-negative results in PA screening in patients with diabetes and hypertension more than 2 months after administration (BMC Endocrine Disorders)

Categories: Medication, News
Tags: ARR, SGLT2 inhibitors

Categories: Medication
Tags: ARR, SGLT2 inhibitors

Efficacy and Safety of the Newer Oral Hypoglycemic Agents in Patients with T2DM During Ramadan: A Systematic Review and Meta-analysis

November 30th 2020

This systematic review and meta-analysis shows clinical benefits with the glucose lowering medications in patients with T2DM who fast during Ramadan (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: Ramadan, Type 2 Diabetes

Categories: Medication
Tags: Ramadan, Type 2 Diabetes

Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by [18F]fluorodeoxyglucose PET‐MRI

November 25th 2020

Metformin dose is an independent determinant of FDG accumulation in the wall and lumen of the large intestine in individuals treated with this drug (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: metformin

Categories: Medication
Tags: metformin

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

November 19th 2020

Among children and young adults with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin production and less exogenous insulin use than placebo (NEJM)

Categories: Medication, News
Tags: golimumab, Type 1 Diabetes

Categories: Medication
Tags: golimumab, Type 1 Diabetes

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

November 18th 2020

Empagliflozin reduced the total burden of cardiovascular complications and all-cause admission to hospital in patients with type 2 diabetes and atherosclerotic cardiovascular disease (The Lancet Diabetes & Endocrinology)

Categories: Medication, News
Tags: Empagliflozin, Type 2 Diabetes

Categories: Medication
Tags: Empagliflozin, Type 2 Diabetes

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

November 17th 2020

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: heart failure, sotagliflozin

Categories: Cardiovascular, Medication
Tags: heart failure, sotagliflozin

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

November 17th 2020

In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events (NEJM)

Categories: Medication, Nephropathy, News
Tags: CKD, sotagliflozin

Categories: Medication, Nephropathy
Tags: CKD, sotagliflozin

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

November 13th 2020

This narrative review gives an overview of the mechanism of action and differences in the underlying pharmacology of the various SGLT2 inhibitors and discusses the key cardiovascular, heart failure and renal outcomes from completed CVOTs for SGLT2 inhibitor (Diabetes Therapy)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

November 10th 2020

In patients with T2DM, SGLT2i as first-line treatment may be associated with decreased events of heart failure hospitalization, acute coronary syndrome, and all-cause mortality, compared with metformin as first-line treatment. However, there may be an increased events of ischemic stroke using SGLT2i compared to metformin (Cardiovascular Diabetology)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Considerations for Insulin-Treated Type 2 Diabetes Patients During Hospitalization: A Narrative Review of What We Need to Know in the Age of Second-Generation Basal Insulin Analogs

November 5th 2020

It is important that HCPs are educated about the differences between standard formulary insulins and second-generation insulins, and the importance of clear communication during patient transitions (Diabetes Therapy)

Categories: Medication, News
Tags: insulin, Type 2 Diabetes

Categories: Medication
Tags: insulin, Type 2 Diabetes

Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study 2012‐2019

November 3rd 2020

In patients with T2DM and CVD, the incidence of cardioprotective GLD initiation increased between 2012‐18, however within two years after dual diagnosis, it remained low (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: CVD, Type 2 Diabetes

Categories: Medication
Tags: CVD, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 41
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaSanofi DiabetesNovo NordiskNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAmgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership